Bristol Myers Squibb

News

Cytokinetics prepares to take on BMS’ Camzyos in HCM

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer

News

BMS, J&J challenges to Medicare negotiations are thrown out

In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson

News

First cGMP Cell Shuttle & Cellares co-founders Omar Kurdi (left) and Fabian Gerlinghaus (right)

BMS preps for CAR-T growth with $380m Cellares deal

Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer Cellares that will be used to supply patients in th

News

Carvykti, Abecma move earlier in multiple myeloma treatment

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one pri

News

Disappointment for BMS as Zeposia fails Crohn’s study

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.

News

BMS completes $14bn takeover of Karuna

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha

Cytokinetics prepares to take on BMS’ Camzyos in HCM

BMS, J&J challenges to Medicare negotiations are thrown out

BMS preps for CAR-T growth with $380m Cellares deal

Carvykti, Abecma move earlier in multiple myeloma treatment

Disappointment for BMS as Zeposia fails Crohn’s study

BMS completes $14bn takeover of Karuna

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Bristol Myers Squibb

Editor's Picks